This was evidenced by significant decrease in expression of phosphorylated VEGFR1 and 2, whereas the expression of the phosphorylated forms of FGFR1/2 and the adaptive scaffold protein FRS-2 in regorafenib-treated GIST cells remained unchanged (Figure 3). This evidence concerns the gene FRS2 and gastrointestinal stromal tumor.